Promoted Content
Promoted Content

Find Clinical Drug Pipeline Developments & Deals by Eisai

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Therapeutic Area filter
    Study Phase filter
      Country filter
        News Type filter
          Company filter
            refresh

            Companies By Therapeutic Area Full Screen

            Development Status Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Undisclosed

            Therapeutic Area: Neurology Product Name: Undisclosed

            Highest Development Status: Discovery Platform Product Type: Small molecule

            Recipient: Wren Therapeutics

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration November 30, 2020

            Details:

            The collaboration will use Wren’s network kinetics drug discovery platform, alongside Eisai’s extensive experience in drug discovery for neurodegenerative disorders, to accelerate the development of clinical candidates.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Adalimumab

            Therapeutic Area: Dermatology Product Name: Humira

            Highest Development Status: Approved Product Type: Large molecule

            Partner/Sponsor/Collaborator: AbbVie Inc

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 27, 2020

            Details:

            Approval is based on the data from a Japanese phase III clinical trial. The proportion of patients achieving at 100 of the target pyoderma gangrenosum ulcer area reduction at Week 26 of Humira administration was 54.5% in the trail.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Lenvatinib

            Therapeutic Area: Oncology Product Name: Lenvima

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 19, 2020

            Details:

            New safety and efficacy data on LENVIMA® (lenvatinib), an orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai, will be presented from two trials in patients with radioactive iodine-refractory differentiated thyroid cancer (RAI-refractory DTC).

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Lenvatinib,Pembrolizumab

            Therapeutic Area: Oncology Product Name: Lenvima

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 10, 2020

            Details:

            CLEAR is a multi-center, randomized, open-label, Phase 3 trial evaluating LENVIMA in combination with KEYTRUDA or in combination with everolimus versus sunitinib alone for the first-line treatment of patients with advanced RCC.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Denileukin Diftitox,Anti-PD-1 agent

            Therapeutic Area: Oncology Product Name: E7777

            Highest Development Status: Preclinical Product Type: Large molecule

            Recipient: Dr. Reddy's Laboratories

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 09, 2020

            Details:

            Combination of E7777 with an anti-PD-1 agent provided clear benefit both in terms of tumor growth control, and a highly significant improvement in overall survival.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Lecanemab

            Therapeutic Area: Neurology Product Name: BAN2401

            Highest Development Status: Phase III Product Type: Large molecule

            Partner/Sponsor/Collaborator: BioArctic AB

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 09, 2020

            Details:

            For the patients who received BAN2401 10 mg/kg either monthly or every other week in the core study, the amyloid levels in the brain were already low when they entered the open-label extension study and remained low.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Aducanumab

            Therapeutic Area: Neurology Product Name: BIIB037

            Highest Development Status: Phase III Product Type: Large molecule

            Recipient: Biogen

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 06, 2020

            Details:

            Data from Study 103 (PRIME) provide supportive evidence of the effectiveness of aducanumab's eventual approval, boosting chances that Biogen's drug could the market for Alzheimer's patients in the future.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Lenvatinib,Everolimus

            Therapeutic Area: Oncology Product Name: Lenvima

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 05, 2020

            Details:

            Data includes an oral presentation on results from a Phase 2 trial evaluating starting doses of LENVIMA in combination with everolimus (LEN+EVE).

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Aducanumab

            Therapeutic Area: Neurology Product Name: BIIB037

            Highest Development Status: Phase III Product Type: Large molecule

            Recipient: Biogen

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 30, 2020

            Details:

            Clinical data from patients with Mild Cognitive Impairment due to Alzheimer’s disease and mild Alzheimer’s disease demonstrate that treatment with aducanumab resulted in the removal of amyloid beta and better clinical outcomes.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Lecanemab

            Therapeutic Area: Neurology Product Name: BAN2401

            Highest Development Status: Phase III Product Type: Large molecule

            Partner/Sponsor/Collaborator: BioArctic AB

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 28, 2020

            Details:

            During the conference, Eisai will hold four presentations and present new information from all three on-going clinical studies with the investigational anti-amyloid beta (Aβ) protofibril antibody BAN2401.

            PharmaCompass